GU Cancers 2020 | KEYNOTE-921: pembrolizumab + docetaxel & prednisone for mCRPC

Name: KEYNOTE-921: pembrolizumab + docetaxel & prednisone for mCRPC
Uploaded: 2020-02-15T15:57:41Z
Description: Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, discusses the KEYNOTE-921 study (NCT03834506) of pembrolizumab plus docetaxel and prednisone for enzalutamide or abiraterone acetate for patients with metastatic CRPC. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Daniel Petrylak • 15 Feb 2020

GU Cancers 2020

Genitourinary Cancer Prostate Cancer Antibodies Checkpoint Inhibitors Docetaxel Pembrolizumab

Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, discusses the KEYNOTE-921 study (NCT03834506) of pembrolizumab plus docetaxel and prednisone for enzalutamide or abiraterone acetate for patients with metastatic CRPC. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.